Arrowhead gets patent for Cyclosert technology platform

By Elaine Rigoli

Tampa, Fla., Aug. 16 - Arrowhead Research Corp. announced that U.S. Patent No. 7,091,192, titled "Linear Cyclodextrin Copolymers," has been issued to the California Institute of Technology and is exclusively licensed to Arrowhead's majority-owned subsidiary, Insert Therapeutics.

This patent is the final U.S. patent to issue from a series of three related applications covering the composition, method of preparation and methods of use of a new class of polymers for delivery of therapeutic compounds, according to a news release.

These polymers, part of a family designated as Insert Therapeutics' proprietary Cyclosert technology platform, represent a significant advance in the use of cyclodextrins for delivery of therapeutic compounds, the release said.

Insert is using Cyclosert technology in its lead drug candidate, IT-101, an experimental drug being studied for the treatment of cancer in clinical trials at City of Hope Cancer Center in Duarte, Calif. IT-101 is a conjugate of one of the Cyclosert polymers and the anticancer small molecule drug camptothecin.

"This patent represents the final piece of the foundation for Insert's extensive portfolio of patents and patent applications relating to its Cyclosert drug delivery systems. It gives us substantial intellectual property protection for IT-101 and other product candidates that we are developing internally," Insert president John Petrovich said in the release.

Arrowhead is a nanotechnology company based in Pasadena, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.